Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair
Pharmacological Reviews · 2024
DOI: 10.1124/pharmrev.124.000927 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Reviews, 2024. Verfasst von Rina Aharoni und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel (Ri.A., Ru.A.); and Department of Neurology, Barzil…. Hauptthemen laut MEDLINE: Glatiramer Acetate, Multiple Sclerosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 173 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel (Ri.A., Ru.A.); and Department of Neurology, Barzilai Medical Center, Ashkelon, Israel, and Faculty of Health Sciences, B…
Zitieren
APA
Aharoni, R., Milo, R., & Arnon, R. (2024). Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair. Pharmacological Reviews. https://doi.org/10.1124/pharmrev.124.000927
Vancouver
Aharoni R, Milo R, Arnon R. Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair. Pharmacological Reviews. 2024. doi:10.1124/pharmrev.124.000927
BibTeX
@article{Aharoni2024,
author = {Aharoni, Rina and Milo, Ron and Arnon, Ruth},
title = {Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair},
journal = {Pharmacological Reviews},
year = {2024},
doi = {10.1124/pharmrev.124.000927}
}
EUVIMED